文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛创伤与烧伤

多发伤患者急性肾损伤发生与早期重复造影检查的安全性:一项回顾性队列研究

Acute kidney injury development in polytrauma and the safety of early repeated contrast studies: A retrospective cohort study.
PubMed 文献 · J Trauma Acute Care Surg · 2022-07-07
一句话结论ICU多发伤患者伤后72小时内接受额外造影剂剂量与急性肾损伤无显著关联,不应因此放弃必要的二次影像检查。

本研究基于机构前瞻性多发伤多器官衰竭数据库,回顾8年数据,纳入存活超过72小时、损伤严重度评分>15的成人ICU多发伤患者663例,按初次影像后接受重复造影检查的次数分组。结果显示急性肾损伤发生率为13.4%,造影剂所致急性肾损伤为14.5%;多因素分析显示72小时内接受额外造影剂剂量与急性肾损伤无显著关联(OR 1.33,95%CI 0.80-2.21,p=0.273)。急性肾损伤与更差结局相关:ICU住院时间8天 vs 3天(p<0.0001)、死亡率16% vs 3.8%(p<0.0001)、多器官衰竭42% vs 6.6%(p<0.0001)。作者认为造影剂所致急性肾损伤的临床意义可能被高估,不应因此妨碍ICU必要的二次影像检查,但需进一步前瞻性研究验证。

要点

  • ICU多发伤患者中,伤后72小时内接受额外造影剂剂量与急性肾损伤无显著关联(OR 1.33,95%CI 0.80-2.21,p=0.273)。
  • 急性肾损伤发生率为13.4%,造影剂所致急性肾损伤(72小时内肌酐升高>25%或>44 μmol/L)为14.5%。
  • 急性肾损伤患者ICU住院时间8天 vs 3天(p<0.0001)、死亡率16% vs 3.8%(p<0.0001)、多器官衰竭42% vs 6.6%(p<0.0001)。
  • 急性肾损伤的危险因素包括更高的ISS(p<0.0007)、年龄较大(p=0.0109)、心率较高(p=0.0327)、收缩压较低(p=0.0007)及基线实验室异常:碱缺失(p=0.0042)、肌酐(p<0.0001)、乳酸(p<0.0001)、血红蛋白(p=0.0085)。
  • 作者认为造影剂所致急性肾损伤的临床意义可能被高估,不应因此妨碍ICU必要的二次影像检查。

适用人群与场景

  • 成人ICU多发伤患者,存活>72小时,损伤严重度评分(ISS)>15。

诊断标准与关键阈值

  • 急性肾损伤诊断采用肾脏病改善全球结局(KDIGO)标准。
  • 造影剂所致急性肾损伤定义为造影剂给药后72小时内肌酐升高>25%或>44 μmol/L。

研究设计与关键结果

  • 回顾性队列研究,基于机构前瞻性多发伤多器官衰竭数据库8年数据;纳入663例多发伤患者(年龄45.3岁[SD 9.1岁];男性75%;ISS 25[四分位距20-34];死亡率5.4%)。
  • 急性肾损伤发生率为13.4%,造影剂所致急性肾损伤为14.5%。
  • 多因素分析:72小时内接受额外造影剂剂量与急性肾损伤无显著关联(OR 1.33,95%CI 0.80-2.21,p=0.273)。
  • 急性肾损伤危险因素:更高的ISS(p<0.0007)、年龄较大(p=0.0109)、心率较高(p=0.0327)、收缩压较低(p=0.0007)、碱缺失(p=0.0042)、肌酐(p<0.0001)、乳酸(p<0.0001)、血红蛋白(p=0.0085)。
  • 急性肾损伤与更差结局相关:ICU住院时间8天 vs 3天(p<0.0001);死亡率16% vs 3.8%(p<0.0001);多器官衰竭42% vs 6.6%(p<0.0001)。

证据类型、等级与局限

  • 证据类型:回顾性队列研究;证据等级:治疗/护理管理;Level III。
  • 局限:原文未报告局限性;作者指出需进一步前瞻性研究验证结果。

对床旁实践的改变

  • 作者认为造影剂所致急性肾损伤的临床意义可能被高估,不应因此妨碍ICU必要的二次影像检查。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The role of repeat intravenous contrast doses beyond initial contrast imaging in the development of acute kidney injury (AKI) for multiple injury patients admitted to the intensive care unit (ICU) is not fully understood. We hypothesized that additional contrast doses are potentially modifiable risk factors for worse outcomes.

METHODS: An 8-year retrospective study of our institutional prospective postinjury multiple organ failure database was performed. Adult ICU admissions that survived >72 hours with Injury Severity Score (ISS) of >15 were included. Patients were grouped based on number of repeat contrast studies received after initial imaging. Initial vital signs, resuscitation data, and laboratory parameters were collected. Primary outcome was AKI (Kidney Disease: Improving Global Outcomes criteria), and secondary outcomes included contrast-induced acute kidney injury (CI-AKI; >25% or >44 μmol/L increase in creatinine within 72 hours of contrast administration), multiple organ failure, length of stay, and mortality.

RESULTS: Six-hundred sixty-three multiple injury patients (age, 45.3 years [SD, 9.1 years]; males, 75%; ISS, 25 (interquartile range, 20-34); mortality, 5.4%) met the inclusion criteria. The incidence of AKI was 13.4%, and CI-AKI was 14.5%. Multivariate analysis revealed that receiving additional contrast doses within the first 72 hours was not associated with AKI (odds ratio, 1.33; confidence interval, 0.80-2.21; p = 0.273). Risk factors for AKI included higher ISS ( p < 0.0007), older age ( p = 0.0109), higher heart rate ( p = 0.0327), lower systolic blood pressure ( p = 0.0007), and deranged baseline blood results including base deficit ( p = 0.0042), creatinine ( p < 0.0001), lactate ( p < 0.0001), and hemoglobin ( p = 0.0085). Acute kidney injury was associated with worse outcomes (ICU length of stay: 8 vs. 3 days, p < 0.0001; mortality: 16% vs. 3.8%, p < 0.0001; MOF: 42% vs. 6.6%, p < 0.0001).

CONCLUSION: There is a limited role of repeat contrast administration in AKI development in ICU-admitted multiple injury patients. The clinical significance of CI-AKI is likely overestimated, and it should not compromise essential secondary imaging from the ICU. Further prospective studies are needed to verify our results.

LEVEL OF EVIDENCE: Therapeutic/Care Management; Level III.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Giles T, Weaver N, Varghese A, et al. Acute kidney injury development in polytrauma and the safety of early repeated contrast studies: A retrospective cohort study. J Trauma Acute Care Surg. 2022. PMID: 35801964. doi:10.1097/TA.0000000000003735

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。